Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.95 USD | +1.97% | -5.70% | -31.28% |
May. 24 | Immunovant Insider Sold Shares Worth $479,233, According to a Recent SEC Filing | MT |
Apr. 20 | Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 164
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 19-05-31 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 21-10-03 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ian Gourley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Maria Alba
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jennifer Moseley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-08-23 |
Jay Stout
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-03-31 |
Chief Tech/Sci/R&D Officer | 66 | 21-05-31 | |
Chau Cheng
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 19-12-17 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 19-12-17 |
Douglas Hughes
BRD | Director/Board Member | 62 | 19-12-17 |
Atul Pande
BRD | Director/Board Member | 69 | 19-12-17 |
Frank Torti
CHM | Chairman | 45 | 19-12-17 |
Eric Venker
BRD | Director/Board Member | 37 | 20-02-17 |
Peter Salzmann
CEO | Chief Executive Officer | 56 | 19-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 145,292,970 | 61,654,201 ( 42.43 %) | 0 | 42.43 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.28% | 4.21B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- IMVT Stock
- Company Immunovant, Inc.